TrakCel, a supplier of cellular orchestration solutions for the cell and gene therapy industry, has launched the latest version of its lead next-generation cellular orchestration platform, OCELLOS 3.0.
 
OCELLOS 3.0 provides the ability to deal with multiple indications and multiple patient populations for each therapy, according to the company. This allows stakeholders to manage all indications, patient groups or trials associated with a therapy from a single TrakCel platform. Data can also be segregated as needed, for example where different sponsors or supply chain partners are involved, reducing challenges of data privacy and control management. The enhancement enables all those involved in the development and delivery of therapies clinically progressing through multiple indications to have a single viewpoint and workflow across the supply and value chains. 
 
TrakCel has added this function to the ‘therapy switcher’ functionality that will remain in OCELLOS 3.0 and allows developers to manage different classes of therapy within the platform. The features have been combined so developers can manage their whole pipeline of therapies from a single platform in an effort to minimize cost of ownership, training and validation burdens. 
 
Additionally, supply and value chains are continuing to internationalize as more companies launch into the CGT sector from different regions and countries. TrakCel has developed the OCELLOS 3.0 user interface to manage multiple time zones and languages more intuitively. This allows a user to view, schedule and manage global manufacturing and logistics, over multiple manufacturing cycles, across a range of local languages, suppliers and time zones. OCELLOS 3.0 will continue to manage different processes, suppliers, patient populations and the chain of identity, labelling and data privacy obligations automatically from one platform.
 
OCELLOS 3.0 also includes the ability to model commercial relationships between healthcare providers and authorized apheresis/cell collection facilities. This increases the sustainability of the complex logistics networks that are needed to facilitate scale-up by only presenting users with an option of partners such as couriers and healthcare facilities that are authorized to deal with their patient, site or therapy.